As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus.

For the second time in CSL Seqirus’ history, OPTIONS is coming home to Australia. Being Australia’s sole influenza vaccine manufacturer and with our deep commitment to public health, it’s extremely fitting and exciting to welcome the conference and the world’s influenza community to this country.

Through the conference, we will not only showcase our public health legacy on home turf, but also demonstrate our expertise in both seasonal and pandemic influenza responses and our ambition to improve global outcomes.

OPTIONS XII provides us with a unique opportunity to share our latest data, real-world evidence, and insights with the global community. These presentations will highlight our continuous drive for innovation, which is at the heart of all we do, and our commitment to leading the fight against influenza and other respiratory viruses. 

We understand the importance of collaboration and partnership in achieving our goals. That's why we are proud to work closely with public health organizations around the world to help make a tangible difference in the lives of people everywhere. 

As we gather at OPTIONS XII and reflect on our rich history and origins, we look forward to engaging discussions, valuable learnings, and the shared pursuit of a healthier future. 

OPTIONS XII is not only a platform for scientific exchange, however, but also a celebration of the same enduring spirit of innovation that defines CSL Seqirus, set in the country where it all began.

King regards,
Dave Ross
Senior Vice President and General Manager, CSL Seqirus